Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
J Neuroimmunol
; 340: 577147, 2020 03 15.
Article
en En
| MEDLINE
| ID: mdl-31951875
ABSTRACT
To assess if markers of complement activation are associated with disease activity, C1q, C3, C3a and sC5b-9 levels in plasma and cerebrospinal fluid (CSF) were determined in 41 patients with clinically isolated syndrome (CIS) or remitting multiple sclerosis (RRMS), in a prospective longitudinal four-year cohort study. C1q in CSF (CSF-C1q) was significantly higher in patients than in controls. Baseline CSF-C1q and CSF-C3a correlated with several neuroinflammatory markers and neurofilament light chain levels. Baseline CSF-C3a correlated with the number of T2 lesions at baseline and new T2 lesions during follow-up. Baseline CSF-C3a was also significantly higher in patients with (nâ¯=â¯21) than in patients without (nâ¯=â¯20) signs of disease activity according to the NEDA-3 concept during one year of follow-up (pâ¯≤â¯.01) Study results support that complement activation is involved in MS pathophysiology and that CSF-C3a carries prognostic information.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Desmielinizantes
/
Activación de Complemento
/
Esclerosis Múltiple Recurrente-Remitente
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Neuroimmunol
Año:
2020
Tipo del documento:
Article